Evaluating the mechanism underlying antitumor effect of interleukin 27 on B cells of chronic lymphocytic leukemia patients.
Adult
Aged
Aged, 80 and over
Apoptosis
/ drug effects
B-Lymphocytes
/ drug effects
Cell Proliferation
/ drug effects
Female
Humans
Interleukins
/ metabolism
Killer Cells, Natural
/ immunology
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Leukocytes, Mononuclear
/ drug effects
Lymphocyte Activation
/ drug effects
Male
Middle Aged
T-Lymphocytes
/ drug effects
IL-27
apoptosis
chronic lymphocyte leukemia
natural killer cell
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
14
02
2020
revised:
19
04
2020
accepted:
19
04
2020
pubmed:
10
5
2020
medline:
7
4
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Chronic lymphocyte leukemia (CLL) is a B-cell malignancy resisted to apoptosis. Recently, some studies indicated that cytokines such as interleukin 27 (IL-27) can reduce B-cell proliferation. The aim of this study is to evaluate the mechanism underlying the proapoptotic effect of IL-27 on B cells of patients with CLL in comparison with B cells of normal subjects. The effect of IL-27 on the antitumor activity of natural killer (NK) and T cells was also evaluated. Peripheral blood mononuclear cells (PBMCs) were isolated from 35 patients with CLL and 15 normal subjects. B cells and PBMCs were cocultured with IL-27 and B cells apoptosis to evaluate proliferation. Both messenger RNA and protein expression of IL-27 and IL-27 receptor were determined using flow cytometry and real-time polymerase chain reaction analysis. To evaluate the apoptotic effect of IL-27 on B cells of patients with CLL, Annexin V-FITC and 7-AAD (BioLegend) fluorescent dyes were used. In addition, the IL-27 effect on activation of T cell and NK cell was determined by determining CD96 molecule expression. IL-27 and IL-27 receptor expression in patients with CLL was significantly lower than that of normal subjects (p < .05). IL-27 enhanced apoptosis of B cells in patients with CLL (p < .05) but this effect was not significantly observed in B cells of normal subjects (p > .05). Consequently, IL-27 reduced the proliferation of B cells and enhanced NK cell activity (p < .05). IL-27, through inducing apoptosis, can exert an inhibitory effect on cancer B cells of CLL patients with minimal effect on normal B cells.
Substances chimiques
Interleukins
0
MYDGF protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9424-9431Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., … Palomares, O. (2011). Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology, 127(3), 701-721.e70.
Billard, C. (2014). Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget, 5(2), 309.
Canale, S., Cocco, C., Frasson, C., Seganfreddo, E., Di Carlo, E., Ognio, E., … Basso, G. (2011). Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia, 25(12), 1815-1824.
Chen, Q., Ghilardi, N., Wang, H., Baker, T., Xie, M.-H., Gurney, A., … deSauvage, F. J. (2000). Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature, 407(6806), 916-920.
Cocco, C., Di Carlo, E., Zupo, S., Canale, S., Zorzoli, A., Ribatti, D., … Airoldi, I. (2012). Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia, 26(6), 1365-1374.
Cocco, C., Giuliani, N., Di Carlo, E., Ognio, E., Storti, P., Abeltino, M., … Airoldi, I. (2010). Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clinical Cancer Research, 16(16), 4188-4197.
Di Meo, S., Airoldi, I., Sorrentino, C., Zorzoli, A., Esposito, S., & Di Carlo, E. (2014). Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clinical Cancer Research, 20(3), 585-594.
Diveu, C., McGeachy, M. J., Boniface, K., Stumhofer, J. S., Sathe, M., Joyce-Shaikh, B., … Kastelein, R. A. (2009). IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. The Journal of Immunology, 182(9), 5748-5756.
Fabbi, M., Carbotti, G., & Ferrini, S. (2017). Dual roles of IL-27 in cancer biology and immunotherapy. Mediators of Inflammation, 2017.
Jurisic, V., Colovic, N., Kraguljac, N., Atkinson, H. D., & Colovic, M. (2008). Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters. Medical Oncology, 25(3), 315-322.
Kamiya, S., Owaki, T., Morishima, N., Fukai, F., Mizuguchi, J., & Yoshimoto, T. (2004). An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. The Journal of Immunology, 173(6), 3871-3877.
Karan-Djurasevic, T., Palibrk, V., Zukic, B., Spasovski, V., Glumac, I., Colovic, M., … Pavlovic, S. (2013). Expression of Bcl2L12 in chronic lymphocytic leukemia patients: Association with clinical and molecular prognostic markers. Medical Oncology, 30(1), 405.
Kokhaei, P., Palma, M., Mellstedt, H., & Choudhury, A. (2005). Biology and treatment of chronic lymphocytic leukemia. Annals of Oncology, 16(Suppl. 2), 113-123.
Larousserie, F., Charlot, P., Bardel, E., Froger, J., Kastelein, R. A., & Devergne, O. (2006). Differential effects of IL-27 on human B cell subsets. The Journal of Immunology, 176(10), 5890-5897.
Larousserie, F., Pflanz, S., Coulomb-L'Herminé, A., Brousse, N., Kastelein, R., & Devergne, O. (2004). Expression of IL-27 in human Th1-associated granulomatous diseases. The Journal of Pathology, 202(2), 164-171.
Liu, L., Wang, S., Shan, B., Shao, L., Sato, A., Kawamura, K., … Tagawa, M. (2008). IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scandinavian Journal of Immunology, 68(1), 22-29.
Pak, F., Barati, M., Shokrolahi, M., & Kokhaei, P. (2014). Tumor immunology and tumor escape mechanisms from immune response. Koomesh, 15, 412-430.
Palma, M., Kokhaei, P., Lundin, J., Choudhury, A., Mellstedt, H., & Osterborg, A. (2006). The biology and treatment of chronic lymphocytic leukemia. Annals of Oncology, 17(Suppl. 10), x144-x154. https://doi.org/10.1093/annonc/mdl252
Pflanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J. F., … Kastelein, R. A. (2004). WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. The Journal of Immunology, 172(4), 2225-2231.
Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., … Vaisberg, E. (2002). IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity, 16(6), 779-790.
Salcedo, R., Stauffer, J. K., Lincoln, E., Back, T. C., Hixon, J. A., Hahn, C., … Wigginton, J. M. (2004). IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8+ T cells. The Journal of Immunology, 173(12), 7170-7182.
Song, X. N., Yang, J. Z., Sun, L. X., Meng, J. B., Zhang, J. Q., Lv, H. Y., & Kong, L. J. (2013). Expression levels of IL-27 and IL-17 in multiple myeloma patients: A higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival. Leukemia Research, 37(9), 1094-1099. https://doi.org/10.1016/j.leukres.2013.06.022
Vuletic, A. M., Jovanic, I. P., Jurišic, V. B., Milovanovic, Z. M., Nikolic, S. S., Tanic, N. T., & Konjevic, G. M. (2015). In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15. Melanoma Research, 25(1), 22-34.
Yoshimoto, T., Morishima, N., Mizoguchi, I., Shimizu, M., Nagai, H., Oniki, S., … Mizuguchi, J. (2008). Antiproliferative activity of IL-27 on melanoma. The Journal of Immunology, 180(10), 6527-6535.
Zorzoli, A., Di Carlo, E., Cocco, C., Ognio, E., Ribatti, D., Ferretti, E., … Airoldi, I. (2012). Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg−/− mice. Clinical Cancer Research, 18(6), 1630-1640. https://doi.org/10.1158/1078-0432.Ccr-11-2432